<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37591957</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>4970</StartPage><MedlinePgn>4970</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4970</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-40734-8</ELocationID><Abstract><AbstractText>In preclinical studies rapamycin was found to target neuroinflammation, by expanding regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) pathogenesis. Herein we report a multicenter, randomized, double-blind trial, in 63 ALS patients who were randomly assigned in a 1:1:1 ratio to receive rapamycin 2&#x2009;mg/m<sup>2</sup>/day,1&#x2009;mg/m<sup>2</sup>/day or placebo (EUDRACT 2016-002399-28; NCT03359538). The primary outcome, the number of patients exhibiting an increase &gt;30% in regulatory T cells from baseline to treatment end, was not attained. Secondary outcomes were changes from baseline of T, B, NK cell subpopulations, inflammasome mRNA expression and activation status, S6-ribosomal protein phosphorylation, neurofilaments; clinical outcome measures of disease progression; survival; safety and quality of life. Of the secondary outcomes, rapamycin decreased mRNA relative expression of the pro-inflammatory cytokine IL-18, reduced plasmatic IL-18 protein, and increased the percentage of classical monocytes and memory switched B cells, although no corrections were applied for multiple tests. In conclusion, we show that rapamycin treatment is well tolerated and provides reassuring safety findings in ALS patients, but further trials are necessary to understand the biological and clinical effects of this drug in ALS.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9244-9782</Identifier><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. jessica.mandrioli@unimore.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. jessica.mandrioli@unimore.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amico</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Statistical and Methodological Support to Clinical Research, Azienda Ospedaliero-Universitaria, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zucchi</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>De Biasi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Banchelli</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Statistical and Methodological Support to Clinical Research, Azienda Ospedaliero-Universitaria, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonini</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo Tartaro</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicini</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1799-6567</Identifier><AffiliationInfo><Affiliation>Unit of Statistical and Methodological Support to Clinical Research, Azienda Ospedaliero-Universitaria, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianferrari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4260-0915</Identifier><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinti</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, University of Modena and Reggio Emilia, 41125, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicenter, Serena Onlus Foundation, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Istituto Maugeri IRCCS Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerardi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicenter, Serena Onlus Foundation, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarlarini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicenter, Serena Onlus Foundation, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Centre, Neurologic Clinic, Maggiore della Carit&#xe0; University Hospital, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0197-1880</Identifier><AffiliationInfo><Affiliation>ALS Centre, Neurologic Clinic, Maggiore della Carit&#xe0; University Hospital, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scognamiglio</LastName><ForeName>Ada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, Neurologic Clinic, Maggiore della Carit&#xe0; University Hospital, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorar&#xf9;</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Regionale Specializzato Malattie del Motoneurone, Azienda Ospedale Universit&#xe0; di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortuna</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauria</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>3rd Neurology Unit and ALS Centre, IRCCS 'Carlo Besta' Neurological Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bella</LastName><ForeName>Eleonora Dalla</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>3rd Neurology Unit and ALS Centre, IRCCS 'Carlo Besta' Neurological Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caponnetto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitatio&#x146; Ophthalmology, Genetics, Mother and Child Disease, Ospedale Policlinico San Martino, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meo</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitatio&#x146; Ophthalmology, Genetics, Mother and Child Disease, Ospedale Policlinico San Martino, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chio</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neurosciences, ALS Centre, University of Turin and Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5122-7243</Identifier><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neurosciences, ALS Centre, University of Turin and Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cossarizza</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5381-1558</Identifier><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Cardiovascular Research, via Irnerio 48, 40126, Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020382">Interleukin-18</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012269">Ribosomal Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020382" MajorTopicYN="N">Interleukin-18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012269" MajorTopicYN="N">Ribosomal Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.M. reports receiving advisory board fees from Biogen, Amylix and Italfarmaco, grant support from Roche, and grant support from Pfizer (active study drug for this study by grant number Wi211892 to J.M.). ACh received consulting fees from Biogen, Cytokinetics, Amylyx. ACa reports receiving advisory board fees from Biogen and Amylix, and grant support from Cytokinetics. GL reports scientific advisory for CSL Behring, Biogen Inc, Vertex Pharmaceuticals Incorporated, Chromocell Corporation, Janssen Pharmaceuticals, Inc, Lilly, and the Bracco Group. C.L. has served as a scientific consultant for Mitsubishi Tanabe Pharma Europe, Cytokinetics, Neuraltus, and Italfarmaco. R.D.A., E.Z., S.D.B., F.B., I.M., C.S., D.L.T., R.V., N.F., G.G., M.P., F.G., C.T., L.M., F.D.M., A.S., G.S., A.F., E.D.B., C.C., G.M., A.Co. declare no competing interests. Disclosure forms provided by the authors are available with the full text of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>17</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37591957</ArticleId><ArticleId IdType="pmc">PMC10435464</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-40734-8</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-40734-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arthur KC, et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharm. 2013;8:888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Lee JD, Woodruff TM, Henderson RD. The peripheral immune system and amyotrophic lateral sclerosis. Front Neurol. 2020;11:279. doi: 10.3389/fneur.2020.00279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00279</ArticleId><ArticleId IdType="pmc">PMC7186478</ArticleId><ArticleId IdType="pubmed">32373052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdani S, et al. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression. Nat. Commun. 2022;13:6733. doi: 10.1038/s41467-022-34526-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34526-9</ArticleId><ArticleId IdType="pmc">PMC9643478</ArticleId><ArticleId IdType="pubmed">36347843</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530. doi: 10.1172/jci.insight.89530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.89530</ArticleId><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahama M, Akira S, Saitoh T. Autophagy limits activation of the inflammasomes. Immunol. Rev. 2018;281:62&#x2013;73. doi: 10.1111/imr.12613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12613</ArticleId><ArticleId IdType="pubmed">29248000</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;ladeau C, Sandhu JK. Aberrant NLRP3 inflammasome activation ignites the fire of inflammation in neuromuscular diseases. Int J. Mol. Sci. 2021;22:6068. doi: 10.3390/ijms22116068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116068</ArticleId><ArticleId IdType="pmc">PMC8200055</ArticleId><ArticleId IdType="pubmed">34199845</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 2014;10:677&#x2013;685. doi: 10.1038/nchembio.1563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1563</ArticleId><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton JO, Sahin M. The neurology of mTOR. Neuron. 2014;84:275&#x2013;291. doi: 10.1016/j.neuron.2014.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.09.034</ArticleId><ArticleId IdType="pmc">PMC4223653</ArticleId><ArticleId IdType="pubmed">25374355</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004;36:585&#x2013;595. doi: 10.1038/ng1362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1362</ArticleId><ArticleId IdType="pubmed">15146184</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, et al. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J. Biol. Chem. 2009;284:27416&#x2013;27424. doi: 10.1074/jbc.M109.031278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.031278</ArticleId><ArticleId IdType="pmc">PMC2785671</ArticleId><ArticleId IdType="pubmed">19651785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chennampally P, et al. A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin. Sci. Rep. 2021;11:18168. doi: 10.1038/s41598-021-97405-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-97405-1</ArticleId><ArticleId IdType="pmc">PMC8438029</ArticleId><ArticleId IdType="pubmed">34518579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc. Natl Acad. Sci. USA. 2012;109:15024&#x2013;15029. doi: 10.1073/pnas.1206362109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206362109</ArticleId><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, et al. Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. Hum. Mol. Genet. 2015;24:1682&#x2013;1690. doi: 10.1093/hmg/ddu580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu580</ArticleId><ArticleId IdType="pubmed">25410659</ArticleId></ArticleIdList></Reference><Reference><Citation>Deivasigamani S, Verma HK, Ueda R, Ratnaparkhi A, Ratnaparkhi GS. A genetic screen identifies Tor as an interactor of VAPB in a Drosophila model of amyotrophic lateral sclerosis. Biol. Open. 2014;3:1127&#x2013;1138. doi: 10.1242/bio.201410066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/bio.201410066</ArticleId><ArticleId IdType="pmc">PMC4232771</ArticleId><ArticleId IdType="pubmed">25361581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, et al. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) Medicines. 2018;97:e111&#x2013;e119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannelli I, et al. Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Commun. 2021;3:fcab141. doi: 10.1093/braincomms/fcab141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab141</ArticleId><ArticleId IdType="pmc">PMC8364666</ArticleId><ArticleId IdType="pubmed">34409288</ArticleId></ArticleIdList></Reference><Reference><Citation>Candela-Boix MR, et al. Population pharmacokinetics models of sirolimus in renal transplant patients: a systematic review. Farm Hosp. 2021;45:77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">35379113</ArticleId></ArticleIdList></Reference><Reference><Citation>Shchegolev Y, et al. Upregulation of Akt/Raptor signaling is associated with rapamycin resistance of breast cancer cells. Chem. Biol. Interact. 2020;330:109243. doi: 10.1016/j.cbi.2020.109243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2020.109243</ArticleId><ArticleId IdType="pubmed">32861747</ArticleId></ArticleIdList></Reference><Reference><Citation>Neklesa TK, Davis RW. Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex. Proc. Natl Acad. Sci. USA. 2008;105:15166&#x2013;15171. doi: 10.1073/pnas.0807712105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807712105</ArticleId><ArticleId IdType="pmc">PMC2567509</ArticleId><ArticleId IdType="pubmed">18812505</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarnath S, et al. Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy. 2010;6:523&#x2013;541. doi: 10.4161/auto.6.4.11811.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.6.4.11811</ArticleId><ArticleId IdType="pmc">PMC3707503</ArticleId><ArticleId IdType="pubmed">20404486</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Shea A. E. et al. Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention. Clin Immunol. 2022:109095.</Citation><ArticleIdList><ArticleId IdType="pubmed">35973640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliandolo A, Giacoppo S, Bramanti P, Mazzon E. NLRP3 inflammasome activation in a transgenic amyotrophic lateral sclerosis model. Inflammation. 2018;41:93&#x2013;103. doi: 10.1007/s10753-017-0667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-017-0667-5</ArticleId><ArticleId IdType="pubmed">28936769</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildiz O, et al. The expression of active CD11b monocytes in blood and disease progression in amyotrophic lateral Sclerosis. Int J. Mol. Sci. 2022;23:3370. doi: 10.3390/ijms23063370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23063370</ArticleId><ArticleId IdType="pmc">PMC8952310</ArticleId><ArticleId IdType="pubmed">35328793</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74:1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci. Rep. 2020;10:15295. doi: 10.1038/s41598-020-72247-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72247-5</ArticleId><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogan I, et al. Multiple layers of B cell memory with different effector functions. Nat. Immunol. 2009;10:1292&#x2013;1299. doi: 10.1038/ni.1814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1814</ArticleId><ArticleId IdType="pubmed">19855380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xe4;ppe U, et al. Cardiac troponin T is elevated and increases longitudinally in ALS patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 2022;23:58&#x2013;65. doi: 10.1080/21678421.2021.1939384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1939384</ArticleId><ArticleId IdType="pubmed">34151677</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalla Bella E, et al. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain. 2021;144:2635&#x2013;2647. doi: 10.1093/brain/awab167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab167</ArticleId><ArticleId IdType="pmc">PMC8557337</ArticleId><ArticleId IdType="pubmed">33905493</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselin F, et al. Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients. CNS Neurosci. Ther. 2022;28:1532&#x2013;1538. doi: 10.1111/cns.13894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13894</ArticleId><ArticleId IdType="pmc">PMC9437233</ArticleId><ArticleId IdType="pubmed">35751632</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T, et al. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study. Eur. J. Neurol. 2023;6:1600&#x2013;1610. doi: 10.1111/ene.15773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15773</ArticleId><ArticleId IdType="pubmed">36899448</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, et al. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD. Mol. Neurodegener. 2021;16:1. doi: 10.1186/s13024-020-00420-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00420-5</ArticleId><ArticleId IdType="pmc">PMC7792109</ArticleId><ArticleId IdType="pubmed">33413517</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. Amyotrophic lateral sclerosis clinical trials and interpretation of functional end points and fluid biomarkers: a review. JAMA Neurol. 2022;79:1312&#x2013;1318. doi: 10.1001/jamaneurol.2022.3282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.3282</ArticleId><ArticleId IdType="pubmed">36251310</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7:412&#x2013;425. doi: 10.4161/auto.7.4.14541.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.7.4.14541</ArticleId><ArticleId IdType="pubmed">21193837</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats KA, et al. Rapamycin increases survival in ALS mice lacking mature lymphocytes. Mol. Neurodegener. 2013;8:31. doi: 10.1186/1750-1326-8-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-31</ArticleId><ArticleId IdType="pmc">PMC3847677</ArticleId><ArticleId IdType="pubmed">24025516</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng CW, Lin MJ, Shen CK. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP. J. Neurogenet. 2015;29:59&#x2013;68. doi: 10.3109/01677063.2015.1077832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01677063.2015.1077832</ArticleId><ArticleId IdType="pubmed">26219309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 2009;210:73&#x2013;79. doi: 10.1016/j.jneuroim.2009.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.02.012</ArticleId><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293&#x2013;1314. doi: 10.1093/brain/awr074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>